Recherche - Page 5 sur 6 - Fideres

What Pharmacy Benefit Managers Don’t Want You to Know

Payment flow and pricing structure are highly complex and nontransparent within the US pharmaceutical industry. No single entity having a

février 10, 2017

Generic Drug Prices: Why U.S. Costs Keep Rising

Generic drug price increases may be more widespread than the scope of any current lawsuit. Fideres has identified over 90

janvier 13, 2017

Twombly Or Not Twombly?

We assess the impact of the Twombly decision on US antitrust class actions. The number of filings has decreased, despite

octobre 7, 2016

Indexers in Hiding: Active Funds That Aren’t So Active

Active share alone can give a biased view of funds’ activeness. Other metrics must be considered alongside active share to

juillet 21, 2016

Interest Rate Swaps and the Collusion Allegations Rocking the Market

Users of the IRS markets fail to benefit from cost reducing liquidity post SEFs. First of class action suits filed. Collusion

novembre 30, 2015

LIBOR’s Legacy: Competition Issues Still Haunt Benchmarks

Fideres has conducted original research into how USD LIBOR panel members consistently extracted monopoly rents. For 2009, these monopoly rents

novembre 11, 2015

Can Bond Rigging Happen In Europe?

30 class actions have been filed in the US alleging manipulation of the auction facility used to issue new US

octobre 21, 2015

Are the Foreign Exchange Markets Rigged? Traders and Transparency Clash

Panel members allegedly engaged in activity to move the overall level of the swap market around the time of the fixing window.

septembre 1, 2015

FX Scandals and Settlements: Is the Era of Market Manipulation Really Over?

Regulatory fines on banks who manipulated foreign exchange benchmarks have globally exceeded $10 billion. Banks may be required to pay

LIBOR Fines: Truth Suppressed or Justice Served?

Deutsche Bank’s fine of £226.8 million is highest yet in the LIBOR scandal. FCA’s report on LIBOR manipulation lacks any